Early Treatment with Anti-VLA-4 mAb Can Prevent the Infiltration and/or Development of Pathogenic CD11b(+)CD4(+) T Cells in the CNS during Progressive EAE

Natalizumab is a humanized monoclonal antibody against the leukocyte adhesion molecule very late antigen (VLA)-4, and is currently an approved therapy for patients with relapsing-remitting multiple sclerosis (RRMS). However, it is unknown whether natalizumab is beneficial for progressive forms of MS...

Descripción completa

Detalles Bibliográficos
Autores principales: Mindur, John E., Ito, Naoko, Dhib-Jalbut, Suhayl, Ito, Kouichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045930/
https://www.ncbi.nlm.nih.gov/pubmed/24896098
http://dx.doi.org/10.1371/journal.pone.0099068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045930/
https://www.ncbi.nlm.nih.gov/pubmed/24896098
http://dx.doi.org/10.1371/journal.pone.0099068

Ejemplares similares